Opinion|Videos|January 10, 2025
MRD Outcomes From CEPHEUS at ASH 2024
Author(s)Saad Z. Usmani, MD, MBA, FACP, FASCO
Saad Z. Usmani, MD, MBA, FACP, discusses how the CEPHEUS study, presented at ASH 2024, along with its expanded analysis of minimal residual disease (MRD) outcomes, provides valuable insights into the role of MRD as a biomarker in multiple myeloma treatment, highlighting its potential to guide therapy decisions and improve patient outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Provide a brief overview of the CEPHEUS study and the expanded analysis of MRD outcomes presented at ASH 2024.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What additional MRD outcomes were presented?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol
2
Cardiology Prices Vary Widely by Insurer and State
3
Medicaid MFN Pricing Could Save $8.6 Billion
4
CRC Treatment Delays Linked to Higher Metastasis Risk, Supporting Pathway-Specific Benchmarks
5